Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Reflections on Asthma Treatment with Omalizumab Mary C. Tobin MD Director, Clinical Services University Consultants in Allergy/Immunology Reflections on Asthma Treatment with Omalizumab Disclosure of Conflict of Interest Information I have the following relationships that exist related to this presentation: Co-Investigator/Investigator initiated research: IgE receptors on neutrophils in IgE mediated asthma Speakers’ Bureau Glaxo-SmithKline Novartis Genetech Disclosure information stated above is current as of November 18, 2008 Omalizumab • Clinical trials with omalizumab= 60 – – – – – – – – – Allergic asthma Seasonal allergic rhinitis Food allergy Eosinophilic esophagitis Atopic dermatitis Bullous pemphigoid Urticaria Cystic fibrosis with ABPA Basic science • Allergy cells • Markers of inflammation • Airway hypersensitivity Treatment of moderate to severe persistent Asthma Anti-IgE QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture. Phase IIIb, Multi-center, Randomized Double-Blind, Placebo Controlled Study of Omalizumab in Subjects with Moderate to Severe Persistent Asthma Inadequately Controlled with High Dose Inhaled Corticosteroids and Long- Acting Beta -Agonists • EXTRA Background: IgE plays a key role in inflammation. A decrease in free IgE causes a decrease in the initiation of Ag responses in patients with asthma. Objective: To evaluate the efficacy, safety and tolerability of SQ injections of Omalizumab vs.. placebo as add-on therapy to high-dose ICS+LABA for subjects with moderate to severe persistent asthma inadequately controlled as judged by asthma exacerbations requiring treatment with oral steroids during a 48 week treatment period. EXTRA • Methods: 850 subjects 12-75 years of age on high dose ICS and LABA with inadequately controlled asthma. Subjects received 48 weeks of study drug (Omalizumab or placebo) in addition to ICS+LABA • Results: Primary outcome: Asthma exacerbations such as ED/hospitalizations, oral steroid use during the 48 week study period EXTRA • Results: – Secondary outcomes: • Change from baseline to week 48 in overall asthma-related quality of life. • Change from baseline to week 48 in nocturnal and daytime asthma symptom scores • Change in baseline to week 48 in the number of puffs/day of beta-agonist rescue medication • Frequency and severity of treatment-emergent adverse events during the 48-week treatment period. Omalizumab • University Consultants in Allergy/Immunology – Retrospective evaluation • 26 patients who have been on or recently started Omalizumab. – 23 patients for asthma (age 13-76 years) » 7 males and 16 females » 22 patients had severe persistent asthma » 1 patient had mild asthma with severe allergic rhinitis and anaphylaxis to IT Omalizumab • 3 patients started Omalizumab for urticaria resistant to multiple antihistamines, montelukast, cytotoxic agents – 1/3 had resolution of urticaria with 6 months of therapy and has been discontinued for 2 months – One of the patients who did not improve has been diagnosed with Hashimoto’s thyroiditis Omalizumab • Asthma patients – 21 patients have had at least 3 months of therapy • 2/21 patients did not respond and received therapy for 12 months-no decrease in steroid use, no improvement in ACT scores • 19 patients had some improvement with decrease in oral steroids, high dose ICS, decrease in beta-agonist use, decrease in nocturnal awakening and improvement in ACT scores. • 14 patients have had dramatic improvement – – – – Step down to moderate persistent Decrease dose of oral steroids to none or less than 9 mg/day Normalization of ACT scores No ED or hospitalization Omalizumab • 3 patients had asthma with nasal polyps – 2/3 patients had a decrease in the size of the polyps and in the number of sinus infections • 2 patients had a component of COPD and seemed to take longer to respond Omalizumab • Issues of concern – Adverse reactions: • First dose- shortness of breath and urticaria-drug stopped by allergist • Sixth dose- pruritic rash-drug stopped by allergist – When should the drug be stopped or restarted? • If patient is responding what adjustments could be made? • Should skin testing be done with the drug to assess potential mechanism? Omalizumab – Issues of Concern: • Patient compliance: – Responders tend to decrease medication too quickly on their own and then have an exacerbation – Responders tend to stop coming because they are better – Insurance companies deny continuing drug because “they don’t need it anymore” Omalizumab • Final reflections: – Patients with asthma should be evaluated for allergies. Allergies are present in at least 50% of asthmatics age 50 years or younger Patients with moderate to severe persistent IgE mediated asthma should be considered for Omalizumab • If there IgE level is less than 30, repeat when off steroid burst for 4 weeks • Risk of adverse reactions is relatively low and benefit can be life-changing Omalizumab • Nagging Questions for the future: – When to stop Omalizumab??????? • 1 patient just stopped after 4.5 years- She had had severe asthma since childhood with multiple hospitalization. She is only on antihistamine, nasal steroid, and montelukast. • 1 patient stopped after 3 years because of college- no update yet – When she stopped Omalizumab prior to this after 6 months she would return to her pre-Omalizumab status- severe persistent and react to minute amounts of peanut. – Some patients stopped coming on there own. Is there any danger in this? – Some patients have been stopped at 12 months who were benefiting from therapy? Is that long enough?